Matches in Wikidata for { <http://www.wikidata.org/entity/Q59273765> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q59273765 description "im April 2016 veröffentlichter wissenschaftlicher Artikel" @default.
- Q59273765 description "wetenschappelijk artikel" @default.
- Q59273765 description "наукова стаття, опублікована у квітні 2016" @default.
- Q59273765 name "178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC" @default.
- Q59273765 name "178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival" @default.
- Q59273765 type Item @default.
- Q59273765 label "178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC" @default.
- Q59273765 label "178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival" @default.
- Q59273765 prefLabel "178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC" @default.
- Q59273765 prefLabel "178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival" @default.
- Q59273765 P1433 Q59273765-88DA39EA-6111-40CB-B3D3-DF38E6C7ACEC @default.
- Q59273765 P1476 Q59273765-EE864742-2EEE-4A1F-928C-4265793B43D2 @default.
- Q59273765 P2093 Q59273765-18220982-0A6E-4243-8CA6-03245A1EF4E5 @default.
- Q59273765 P2093 Q59273765-5D743C6B-7672-4179-938F-5A090E175DBF @default.
- Q59273765 P2093 Q59273765-9A3D09E1-C413-42A2-A203-ED52F913053B @default.
- Q59273765 P2093 Q59273765-A55DE465-332E-40C4-921D-792D60848EEA @default.
- Q59273765 P2093 Q59273765-AD847E87-B2F7-475D-A0D2-0770A7D75D3D @default.
- Q59273765 P2093 Q59273765-C4A92660-00B7-46C0-AA64-293A39D560A0 @default.
- Q59273765 P2093 Q59273765-C8DDEC1A-A5AD-4683-BF8A-55199F425E56 @default.
- Q59273765 P2093 Q59273765-CD1144ED-320A-4B09-AEF8-C5F26489F440 @default.
- Q59273765 P2093 Q59273765-D7CF7797-DD71-49FF-8FB5-CAF45C05C71B @default.
- Q59273765 P304 Q59273765-C8E8904E-4EB5-43DB-B67F-8090117ACC5E @default.
- Q59273765 P31 Q59273765-05D2E7E6-501F-4A4E-B36D-11C15E4985E6 @default.
- Q59273765 P356 Q59273765-DFB6EC21-A926-42B9-BD9A-8E1C868EFB3B @default.
- Q59273765 P433 Q59273765-A3141212-2724-45D6-B29D-A72C7AB8A215 @default.
- Q59273765 P478 Q59273765-225A1246-9AE6-4E34-8A47-ADD853AE6137 @default.
- Q59273765 P577 Q59273765-17CE29F9-96DF-43AC-8C53-4E41EF07B571 @default.
- Q59273765 P921 Q59273765-2BE06337-5A59-4DB6-8DF7-BA2B04FB9339 @default.
- Q59273765 P921 Q59273765-52856843-2D9A-499D-AE97-176A104A5B62 @default.
- Q59273765 P356 S1556-0864(16)30288-X @default.
- Q59273765 P1433 Q2448056 @default.
- Q59273765 P1476 "178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC" @default.
- Q59273765 P2093 "A.T. Shaw" @default.
- Q59273765 P2093 "D. Tan" @default.
- Q59273765 P2093 "D.-W. Kim" @default.
- Q59273765 P2093 "E. Felip" @default.
- Q59273765 P2093 "G. Liu" @default.
- Q59273765 P2093 "J. Signorovitch" @default.
- Q59273765 P2093 "J. Zhang" @default.
- Q59273765 P2093 "M. Thomas" @default.
- Q59273765 P2093 "T. Szczudlo" @default.
- Q59273765 P304 "S134-S135" @default.
- Q59273765 P31 Q13442814 @default.
- Q59273765 P356 "10.1016/S1556-0864(16)30288-X" @default.
- Q59273765 P433 "4" @default.
- Q59273765 P478 "11" @default.
- Q59273765 P577 "2016-04-01T00:00:00Z" @default.
- Q59273765 P921 Q21011233 @default.
- Q59273765 P921 Q3658562 @default.